El interés en corto de Mattr da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Mattr. Los datos de interés en corto se actualizan cada dos semanas.

Mattr (OTC:MTTRF) Bolsa, Informe de interés en corto

Mattr Corp is a materials technology company broadly serving critical infrastructure markets, including transportation, communication, water management, energy, and electrification. The company operates through a network of fixed manufacturing and service facilities. Its business segments are Composite Technologies and Connection Technologies. A majority of its revenue is generated from the Composite Technologies segment which manufactures flexible composite pipes used predominantly for oil and gas gathering lines, and other applications operating under the Flexpipe brand. Under the Xerxes brand, this segment also manufactures FRP underground storage tanks for retail fuel and other markets. Geographically, the company derives maximum revenue from the United States of America.

Mattr Corp

<p>Alliance Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AENT#NASDAQ">AENT</a>) reported quarterly earnings of $0.04 per share. This is a 157.14 percent increase over losses of $(0.07) per share from the same period last year.  The company reported $213.04 million in sales this quarter. This is a 0.87 percent increase over sales of $211.20 million the same period last year.</p>


Earnings

News

AENT

Alliance Entertainment Q3 EPS $0.04 Up From $(0.07) YoY, Sales $213.04M Up From $211.20M YoY

<p>Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) narrows FY2025 sales outlook from $20.00 million-$34.50 million to $20.00 million-$25.00 million vs $41.49 million estimate.</p>


Guidance

WKSP

Worksport Narrows FY2025 Sales Guidance from $20.00M-$34.50M to $20.00M-$25.00M vs $41.49M Est

<p>Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) reported quarterly earnings of $2.39 per share which beat the analyst consensus estimate of $2.31 by 3.46 percent. This is a 14.35 percent increase over earnings of $2.09 per share from the same period last year.  The company reported quarterly sales of $7.10 billion which missed the analyst consensus estimate of $7.13 billion by 0.38 percent.  This is a 6.83 percent increase over sales of $6.65 billion the same period last year.</p>


Earnings Beats

Earnings Misses

AMAT

Applied Mat Q2 Adj. EPS $2.39 Beats $2.31 Estimate, Sales $7.10B Miss $7.13B Estimate

<p>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.27 by 14.81 percent. This is a 24 percent increase over earnings of $0.25 per share from the same period last year.  The company reported quarterly sales of $138.29 million which beat the analyst consensus estimate of $133.73 million by 3.41 percent.  This is a 17.14 percent increase over sales of $118.06 million the same period last year.</p>


DOCS

Doximity Q4 Adj. EPS $0.31 Beats $0.27 Estimate, Sales $138.29M Beat $133.73M Estimate

<p><i>Cites Evidence That the Company is Not Living Up to Its Potential, As Demonstrated By 26% Year-To-Date Share Price Decline, Underperformance Versus Benchmarks, Precipitous 11% Drop Post-First Quarter Earnings and Fresh 52-Week Low</i></p>
<p><i>Highlights Concerns About Dynavax's Apparent Contentment Regarding Heplisav's Slowing Market Growth Expressed on Recent Earnings Call</i></p>
<p><i>Believes Directors with Shareholder-Aligned Perspective, Vaccine Commercialization Expertise and Capital Allocation Experience are Essential to Critically Evaluate the Company's Strategy and Realize the Full Value of Heplisav</i></p>
<p><i>Urges Shareholders to Vote <strong>FOR</strong> Deep Track's Four Highly Qualified Director Nominees</i></p>


DVAX

Deep Track Capital Issues Letter To Dynavax Technologies Shareholders

<p>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 15.79 percent increase over losses of $(0.19) per share from the same period last year.  The company reported quarterly sales of $9.89 million which beat the analyst consensus estimate of $4.07 million by 143.13 percent.</p>


GOSS

Gossamer Bio Q1 EPS $(0.16) Beats $(0.18) Estimate, Sales $9.89M Beat $4.07M Estimate

<p>Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.96) by 9.38 percent. This is a 40 percent increase over losses of $(1.75) per share from the same period last year.  The company reported quarterly sales of $2.24 million which missed the analyst consensus estimate of $3.72 million by 39.81 percent.  This is a 336.96 percent increase over sales of $512.64 thousand the same period last year.</p>


Worksport Q1 GAAP EPS $(1.05) Misses $(0.96) Estimate, Sales $2.24M Miss $3.72M Estimate

<p>SolarBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUUN#NASDAQ">SUUN</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.01) by 2200 percent.  The company reported quarterly sales of $9.00 million which missed the analyst consensus estimate of $12.66 million by 28.88 percent.</p>


SUUN

SolarBank Q3 EPS $(0.23) Misses $(0.01) Estimate, Sales $9.00M Miss $12.66M Estimate

<p>As THC pouches slowly gain traction in the cannabis industry, new commentary from economist <strong>Beau Whitney</strong> suggests the potential may be far greater than previously understood—<em>if</em> key barriers are addressed.</p>
<p>Whitney, founder of <strong>Whitney Economics</strong> and one of the most cited cannabis economists in the U.S., told Benzinga that THC pouches could act as a direct substitute for chewing tobacco, which is a global market estimated to be worth between $20 billion and $30 billion annually.</p>
<p>"This is about the same as all of the cannabis sold in the U.S. in 2024, regardless of delivery mechanism," Whitney noted.</p>
<p>The comparison casts new light on the opportunity cannabis pouches could represent, not as a novelty but as a serious commercial category with global relevance.</p>
<p>But realizing that potential won&#8217;t be easy.</p>
<p><strong><em>Also read: <a href="https://www.benzinga.com/general/health-care/25/02/43666635/zyn-changed-nicotine-forever-are-cannabis-pouches-the-next-big-thing">Zyn Changed Nicotine Forever &#8211; Are Cannabis Pouches The Next Big Thing?</a></em></strong></p>
<p>Whitney pointed out that flavor bans—already targeting tobacco and vape products in multiple jurisdictions—could hinder the adoption of THC pouches, particularly if they follow the same regulatory trajectory due to concerns about youth appeal.</p>
<p>He also emphasized that consumer conversion will be key.</p>
<p>"In the short run, it would have to be about marketing and converting the consumer away from tobacco and into THC," Whitney said.</p>
<p>Some parallels already exist. For example, hemp flower has been marketed as a tobacco cessation tool, allowing consumers to retain the ritual of smoking without the addictive qualities of nicotine. According to Whitney, this proves that replacement behavior is viable—but scaling it into the pouch format will require structural changes at the regulatory level.</p>
<p>"It is viable," Whitney concluded, "but a lot would have to fall into place globally from a reform perspective to make this happen."</p>
<p>With nicotine pouches like Zyn reshaping the tobacco industry and companies like <strong>Cannadips</strong> and <strong>Juana Dips</strong> working to apply that model to cannabis, Whitney's comments add a fresh layer of urgency to the conversation: the market is waiting, but the window may not stay open forever.</p>
<p><em>Photo: Shutterstock</em></p>


Cannabis

The $30 Billion Question: Can Cannabis Pouches Do What Zyn Did For Nicotine?

<p>Bit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.06) by 433.33 percent. This is a 174.42 percent decrease over earnings of $0.43 per share from the same period last year.  The company reported quarterly sales of $25.10 million which beat the analyst consensus estimate of $24.89 million by 0.82 percent.  This is a 17.16 percent decrease over sales of $30.30 million the same period last year.</p>


BTBT

Bit Digital Q1 EPS $(0.32) Misses $(0.06) Estimate, Sales $25.10M Beat $24.89M Estimate

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Fiserv</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with FI, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 28 uncommon options trades for Fiserv.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 21% bullish and 46%, bearish.</p>
<p>Out of all of the special options we uncovered, 22 are puts, for a total amount of $2,052,565, and 6 are calls, for a total amount of $337,936.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $240.0 for Fiserv during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Fiserv options trades today is 253.38 with a total volume of 4,700.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Fiserv's big money trades within a strike price range of $130.0 to $240.0 over the last 30 days.</p>
<h3>Fiserv 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747339311_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$34.6</td>
<td>$33.7</td>
<td>$34.5</td>
<td>$190.00</td>
<td>$348.4K</td>
<td align="right">17</td>
<td align="right">201</td>
</tr>
<tr>
<td>FI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$37.8</td>
<td>$36.7</td>
<td>$37.8</td>
<td>$200.00</td>
<td>$260.8K</td>
<td align="right">590</td>
<td align="right">81</td>
</tr>
<tr>
<td>FI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.9</td>
<td>$4.3</td>
<td>$4.3</td>
<td>$160.00</td>
<td>$230.6K</td>
<td align="right">19</td>
<td align="right">502</td>
</tr>
<tr>
<td>FI</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$71.4</td>
<td>$68.6</td>
<td>$70.0</td>
<td>$240.00</td>
<td>$182.0K</td>
<td align="right">27</td>
<td align="right">26</td>
</tr>
<tr>
<td>FI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.7</td>
<td>$2.2</td>
<td>$2.55</td>
<td>$180.00</td>
<td>$178.4K</td>
<td align="right">364</td>
<td align="right">973</td>
</tr>
</tbody>
</table>
</p>
<h3>About Fiserv</h3>
<p>Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Through the merger with First Data in 2019, Fiserv also provides payment processing services for merchants. About 10% of the company's revenue is generated internationally.</p>
<p>Following our analysis of the options activities associated with Fiserv, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Fiserv Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 20,118,128, the FI's price is down by -16.36%, now at $158.8. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 69 days.</li>
</ul>
<h3>What The Experts Say On Fiserv</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $241.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Susquehanna keeps a Positive rating on Fiserv with a target price of $240.<br />
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Fiserv with a target price of $232.<br />
&#x2A; An analyst from Keefe, Bruyette &amp; Woods has decided to maintain their Outperform rating on Fiserv, which currently sits at a price target of $240.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Fiserv with a target price of $240.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Fiserv with a target price of $255. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Fiserv options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

Smart Money Is Betting Big In Fiserv Options

<p>Deep-pocketed investors have adopted a bearish approach towards Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BAC usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 43 extraordinary options activities for Bank of America. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 32% leaning bullish and 58% bearish. Among these notable options, 29 are puts, totaling $1,979,073, and 14 are calls, amounting to $1,203,917.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $35.0 to $50.0 for Bank of America over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Bank of America stands at 8304.32, with a total volume reaching 131,457.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Bank of America, situated within the strike price corridor from $35.0 to $50.0, throughout the last 30 days.</p>
<h3>Bank of America Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747339306_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$2.91</td>
<td>$2.89</td>
<td>$2.91</td>
<td>$44.00</td>
<td>$291.0K</td>
<td>3.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$11.3</td>
<td>$11.2</td>
<td>$11.25</td>
<td>$35.00</td>
<td>$225.0K</td>
<td>19.0K</td>
<td>200</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$7.2</td>
<td>$7.15</td>
<td>$7.19</td>
<td>$38.00</td>
<td>$215.7K</td>
<td>5.2K</td>
<td>305</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/18/26</td>
<td>$7.6</td>
<td>$7.5</td>
<td>$7.6</td>
<td>$50.00</td>
<td>$155.8K</td>
<td>27</td>
<td>260</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.14</td>
<td>$0.13</td>
<td>$0.14</td>
<td>$43.50</td>
<td>$122.9K</td>
<td>1.4K</td>
<td>17.9K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Bank of America</h3>
<p>Bank of America is one of the largest financial institutions in the United States, with more than $3.2 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.</p>
<p>In light of the recent options history for Bank of America, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Bank of America's Current Market Status</h3>
<ul>
<li>With a trading volume of 33,077,519, the price of BAC is down by -0.27%, reaching $44.62.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 62 days from now.</li>
</ul>
<h3>What The Experts Say On Bank of America</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $48.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Keefe, Bruyette &amp; Woods continues to hold a Outperform rating for Bank of America, targeting a price of $52.<br />
&#x2A; An analyst from UBS persists with their Buy rating on Bank of America, maintaining a target price of $50.<br />
&#x2A; Maintaining their stance, an analyst from Argus Research continues to hold a Buy rating for Bank of America, targeting a price of $47.<br />
&#x2A; An analyst from Piper Sandler has decided to maintain their Neutral rating on Bank of America, which currently sits at a price target of $42.<br />
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Bank of America with a target price of $51. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bank of America with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Bank of America Options Trading: A Deep Dive into Market Sentiment

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Merck &amp; Co</strong>.</p>
<p>Looking at options history for Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) we detected 18 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.</p>
<p>From the overall spotted trades, 8 are puts, for a total amount of $622,082 and 10, calls, for a total amount of $2,036,471.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $90.0 for Merck &amp; Co over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Merck &amp; Co's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Merck &amp; Co's substantial trades, within a strike price spectrum from $60.0 to $90.0 over the preceding 30 days.</p>
<h3>Merck &amp; Co Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747339301_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$5.0</td>
<td>$4.8</td>
<td>$4.9</td>
<td>$90.00</td>
<td>$980.0K</td>
<td>236</td>
<td>2.1K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$10.45</td>
<td>$10.1</td>
<td>$10.45</td>
<td>$80.00</td>
<td>$726.2K</td>
<td>19.0K</td>
<td>697</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$1.52</td>
<td>$1.46</td>
<td>$1.49</td>
<td>$65.00</td>
<td>$186.2K</td>
<td>16.3K</td>
<td>1.3K</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.16</td>
<td>$2.1</td>
<td>$2.12</td>
<td>$70.00</td>
<td>$171.2K</td>
<td>14.2K</td>
<td>7.0K</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$6.35</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$79.00</td>
<td>$76.2K</td>
<td>569</td>
<td>200</td>
</tr>
</tbody>
</table>
</p>
<h3>About Merck &amp; Co</h3>
<p>Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.</p>
<p>Having examined the options trading patterns of Merck &amp; Co, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Merck &amp; Co</h3>
<ul>
<li>Currently trading with a volume of 12,034,764, the MRK's price is up by 1.57%, now at $74.62. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 75 days.</li>
</ul>
<h3>What Analysts Are Saying About Merck &amp; Co</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $94.67.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $115.<br />
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $85.<br />
&#x2A; An analyst from Citigroup downgraded its action to Neutral with a price target of $84. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Merck &amp; Co options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Decoding Merck & Co's Options Activity: What's the Big Picture?

<p>Analysts' ratings for Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $64.75, along with a high estimate of $81.00 and a low estimate of $41.00. Experiencing a 14.52% decline, the current average is now lower than the previous average price target of $75.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747339277_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Jefferies Financial Gr by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$62.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jefferies Financial Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jefferies Financial Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Jefferies Financial Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Jefferies Financial Gr's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/JEF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Jefferies Financial Gr analyst ratings.</strong></a></p>
<h2>Get to Know Jefferies Financial Gr Better</h2>
<p>Jefferies Financial Group Inc is a full-service investment banking and capital markets firm. It has two reportable segments; Investment Banking and Capital Markets which is also the majority revenue generating segment, includes securities, commodities, corporate lending, futures and foreign exchange capital markets activities and its investment banking business, which provides underwriting and financial advisory services to clients across different sectors. The Asset Management reportable business segment provides alternative investment management services to investors in the U.S. and overseas and generates investment income from capital invested in and managed by it or its affiliated asset managers. Operates geographically in America, Europe and Middle East, Asia Pasific.</p>
<h3>Key Indicators: Jefferies Financial Gr's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Jefferies Financial Gr's revenue growth over a period of 3M has faced challenges. As of 28 February, 2025, the company experienced a revenue decline of approximately <strong>-3.1%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>5.17%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Jefferies Financial Gr's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.26%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Jefferies Financial Gr's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.19%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Jefferies Financial Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>2.31</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Expert Outlook: Jefferies Financial Gr Through The Eyes Of 4 Analysts

<p>Throughout the last three months, 6 analysts have evaluated Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $40.0, a high estimate of $48.00, and a low estimate of $28.00. This current average represents a 0.42% decrease from the previous average price target of $40.17. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747339257_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Virtu Finl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Kaimon Chung</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$42.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$56.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Virtu Finl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Virtu Finl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Virtu Finl's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Virtu Finl's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VIRT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Virtu Finl analyst ratings.</strong></a></p>
<h2>Delving into Virtu Finl's Background</h2>
<p>Virtu Financial Inc is a financial firm that leverages cutting edge technology to deliver liquidity to the global markets and innovative, transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.</p>
<h3>Virtu Finl: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Virtu Finl displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>30.34%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Virtu Finl's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>11.14%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Virtu Finl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.28%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Virtu Finl's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.57%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>5.99</strong>, Virtu Finl faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VIRT

Deep Dive Into Virtu Finl Stock: Analyst Perspectives (6 Ratings)

<p>Across the recent three months, 10 analysts have shared their insights on IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for IQVIA Hldgs, presenting an average target of $189.9, a high estimate of $232.00, and a low estimate of $160.00. This current average represents a 17.25% decrease from the previous average price target of $229.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747339249_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of IQVIA Hldgs by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$161.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Rajesh Kumar</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Hold</td>
<td>$160.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$216.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$170.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$242.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$232.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IQVIA Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of IQVIA Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of IQVIA Hldgs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of IQVIA Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IQV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on IQVIA Hldgs analyst ratings.</strong></a></p>
<h2>Discovering IQVIA Hldgs: A Closer Look</h2>
<p>Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.</p>
<h3>A Deep Dive into IQVIA Hldgs's Financials</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, IQVIA Hldgs showcased positive performance, achieving a revenue growth rate of <strong>2.46%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>6.5%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.13%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> IQVIA Hldgs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.92%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> IQVIA Hldgs's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.43</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into IQVIA Hldgs Stock: Analyst Perspectives (10 Ratings)

<p>In the current market session, <strong>Boyd Gaming Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>)</strong> stock price is at $76.00, after a <strong>0.11%</strong> decrease. However, over the past month, the company's stock spiked by <strong>16.57%</strong>, and in the past year, by <strong>37.07%</strong>. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1747339244_0.png" alt="Past Year Chart" /></p>

<h3>Evaluating Boyd Gaming P/E in Comparison to Its Peers</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Boyd Gaming has a lower P/E than the aggregate P/E of <strong>40.77</strong> of the Hotels, Restaurants &amp; Leisure industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1747339244_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Intraday Update

P/E Ratio Insights for Boyd Gaming

<p>Ratings for Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) were provided by 21 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">9</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $236.9, a high estimate of $260.00, and a low estimate of $190.00. This current average reflects an increase of 6.11% from the previous average price target of $223.26. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747339240_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Zscaler among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Taz Koujalgi</td>
<td>Roth Capital</td>
<td>Announces</td>
<td>Neutral</td>
<td>$215.00</td>
<td>-</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$235.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Todd Weller</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$255.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Tal Liani</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$242.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$233.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zscaler. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zscaler compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Zscaler's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>To gain a panoramic view of Zscaler's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ZS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Zscaler analyst ratings.</strong></a></p>
<h2>Get to Know Zscaler Better</h2>
<p>Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.</p>
<h3>Unraveling the Financial Story of Zscaler</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Zscaler's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>23.41%</strong> as of 31 January, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Zscaler's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-1.19%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Zscaler's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-0.51%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Zscaler's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.16%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Zscaler's debt-to-equity ratio is below the industry average at <strong>0.77</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Zscaler Stock

<p><strong>West Pharmaceutical Servs's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has risen 80.08% since its last report. The company recently reported that it has <strong>2.52 million shares sold short</strong>, which is 4.61% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.9 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747339235_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 7.20%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

How Do Investors Really Feel About West Pharmaceutical Servs?

<p><strong>NOV's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) short percent of float has risen 149.92% since its last report. The company recently reported that it has <strong>26.27 million shares sold short</strong>, which is 15.22% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 5.8 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>NOV Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747339229_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for NOV has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing NOV's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, NOV's peer group average for short interest as a percentage of float is 9.08%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Comments

Mattr

Interés en corto

Mattr (OTC:MTTRF) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL